of the clinical manifestations of NLRC4 hyperactivity in September 2014. Since that time, we have been continuously working to link this genotypic observation with the associated phenotypes of early-onset enterocolitis, Macrophage Activation Syndrome (MAS), and chronically elevated serum IL-18. We have continued to identify that MAS is uniquely marked by elevated IL-18, and this IL-18 is bioactive. We have further been measuring the natural antagonist of IL-18, the IL-18 binding protein IL-18BP), and find this to be highly elevated only during highly active disease in both MAS and in the related condition Hemophagocytic Lymphohistiocytosis (HLH). We find that IL-18BP is not necessarily induced by IL-18 directly, but correlates with other cytokines known to be induced by Interferon gamma. We anticipate publication of the first MAS patient treated with recombinant IL-18BP within the next month, and we are actively working to develop a small, multi-center study to follow up on this observation.